bioAffinity Technologies Files 8-K
Ticker: BIAFW · Form: 8-K · Filed: Oct 9, 2024 · CIK: 1712762
Sentiment: neutral
Topics: 8-k, regulatory-filing, financial-statements
Related Tickers: BIAF
TL;DR
BIAF filed an 8-K on Oct 9th, mostly procedural stuff, check exhibits for details.
AI Summary
On October 9, 2024, bioAffinity Technologies, Inc. filed an 8-K report detailing a Regulation FD Disclosure and other events. The filing includes financial statements and exhibits, but specific financial figures or significant business developments are not detailed in the provided text.
Why It Matters
This filing indicates bioAffinity Technologies, Inc. is making a regulatory disclosure and providing updated financial information to the SEC.
Risk Assessment
Risk Level: low — The filing is primarily procedural and regulatory, with no immediate indication of significant financial distress or major positive developments.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- October 9, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-41463 (commission_file_number) — SEC File Number
- 46-5211056 (irs_number) — I.R.S. Employer Identification Number
- 3300 Nacogdoches Road , Suite 216 San Antonio , Texas 78217 (address) — Principal executive office address
FAQ
What is the primary purpose of this 8-K filing by bioAffinity Technologies, Inc.?
The primary purpose is to report a Regulation FD Disclosure, other events, and to file financial statements and exhibits as of October 9, 2024.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is October 9, 2024.
In which state was bioAffinity Technologies, Inc. incorporated?
bioAffinity Technologies, Inc. was incorporated in Delaware.
What is the SEC file number for bioAffinity Technologies, Inc.?
The SEC file number for bioAffinity Technologies, Inc. is 001-41463.
What is the principal executive office address of bioAffinity Technologies, Inc.?
The principal executive office address is 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.
Filing Stats: 713 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2024-10-09 09:16:24
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 50KB
- ex99-1.htm (EX-99.1) — 22KB
- ex99-1_001.jpg (GRAPHIC) — 19KB
- ex99-1_002.jpg (GRAPHIC) — 7KB
- 0001493152-24-040539.txt ( ) — 334KB
- biaf-20241009.xsd (EX-101.SCH) — 4KB
- biaf-20241009_def.xml (EX-101.DEF) — 29KB
- biaf-20241009_lab.xml (EX-101.LAB) — 36KB
- biaf-20241009_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 9, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Registrant) By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer -3-